GlassScriptPhysician profile
Sheri N Mitchell
NPI 1407419856
$2,586.66
in general payments reported to CMS, 2019-2025
21 companies · $459 in 2025
The $459 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,028 · 2022: $535 · 2023: $197 · 2024: $368 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $635.50 | 2021-2025 | Wegovy |
| Lilly USA, LLC | $556.00 | 2021-2025 | Zepbound, Mounjaro |
| Abbvie INC. | $242.46 | 2021-2022 | |
| Esperion Therapeutics, INC. | $189.57 | 2021-2022 | |
| Amarin Pharma, INC. | $172.51 | 2021-2022 | |
| Madrigal Pharmaceuticals | $146.22 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $129.17 | 2021-2022 | |
| Amgen INC. | $87.44 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $80.52 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $54.69 | 2021 | |
| Boston Scientific Corporation | $49.76 | 2025 | Overstitch Endoscopic Suturing System |
| E.R. Squibb & Sons, L.L.C. | $48.73 | 2024 | Reblozyl |
| Corcept Therapeutics | $32.54 | 2021 | |
| Celgene Corporation | $31.80 | 2024 | Reblozyl |
| Medicure Pharma INC. | $28.68 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $19.33 | 2021 | |
| Antares Pharma, INC. | $17.69 | 2021 | |
| Teleflex LLC | $17.23 | 2023 | Titan Sgs Standard Gastric Stapler |
| Regeneron Healthcare Solutions, INC. | $17.02 | 2022 | |
| Amryt Pharma Holdings LTD | $15.50 | 2021 | |
| Mirati Therapeutics, INC. | $14.30 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheri Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.